ERCC1 and in situ carcinoma: 71.3% (308/432) of cases was ERCC1 positive. Ta = 3.2% T1 = 11.7% T2 = 21.4% T3 = 45.1% T4 = 18.5%CIS = 8.1%LG = 20.8%HG = 79.2%